ReviewBioMed research international2017
The Rising Phoenix-Progesterone as the Main Target of the Medical Therapy for Leiomyoma.
Review in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Deep learning assisted detection and segmentation of uterine fibroids using multi-orientation magnetic resonance imaging.Abdominal radiology (New York) · 2025Article
- The effect of ulipristal acetate on tumor necrosis factor α, insulin-like growth factor 1, and plasminogen activator inhibitor-1 serum levels in patients with symptomatic uterine fibroids.Archives of medical science : AMS · 2024Article
- The Significance of Measuring Vitamin D Serum Levels in Women with Uterine Fibroids.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside.International journal of molecular sciences · 2020Review
- Uterine fibroids in menopause and perimenopause.Menopause (New York, N.Y.) · 2020Review
- The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.International journal of molecular sciences · 2019Review
- The Role of Tumor Necrosis Factor α in the Biology of Uterine Fibroids and the Related Symptoms.International journal of molecular sciences · 2018Review
- Oestrogen receptor alpha PvuII polymorphism and uterine fibroid incidence in Caucasian women.Przeglad menopauzalny = Menopause review · 2018Article
- Vitamin D and Uterine Fibroids-Review of the Literature and Novel Concepts.International journal of molecular sciences · 2018Review
- Alpha-Tocopherol Serum Levels Are Increased in Caucasian Women with Uterine Fibroids: A Pilot Study.BioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leiomyomas, also known as uterine fibroids, are a common benign tumor in women of reproductive age. These lesions disrupt the function of the uterus causing menorrhagia and pelvic pressure as well as reproductive disorders. These women pose a true challenge for clinicians in the attempt of choosing the suitable treatment for each patient. Patient's age, interest in fertility preservation, and leiomyoma location and size are all factors to be taken into account when deciding upon the preferable therapeutic option. For the past few decades, surgical treatment was the only reliable long-term treatment available. A variety of surgical approaches have been developed over the years but these developments have come at the expense of other treatment options. The classical medical treatment includes gonadotropin-releasing hormone (GnRH) agonists and antagonists. These agents are well known for their limited clinical effect as well as their broad spectrum of side effects, inspiring a need for new pharmacological treatments. In recent years, promising results have been reported with the use of selective progesterone receptor modulators (SPRM). Long-term clinical trials have shown a reduction in bleeding and shrinkage of leiomyoma mass. These results instill hope for women suffering from symptomatic leiomyomas seeking an effective, long-term medical option for their condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.